Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

DOI 機関リポジトリ (HANDLE) 機関リポジトリ (HANDLE) HANDLE PubMed オープンアクセス
  • 田村, 友和
    Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University
  • 伊東, 潤平
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo
  • 瓜生, 慧也
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo; Graduate School of Medicine, The University of Tokyo
  • Zahradnik, Jiri
    Department of Biomolecular Sciences, Weizmann Institute of Science; First Medical Faculty at Biocev, Charles University
  • 紀田, 泉
    Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University
  • 安楽, 佑樹
    Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University
  • Nasser, Hesham
    Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University; Department of Clinical Pathology, Faculty of Medicine, Suez Canal University
  • Shofa, Maya
    Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki
  • 小田, 義崇
    Department of Cancer Pathology, Faculty of Medicine, Hokkaido University
  • Lytras, Spyros
    Medical Research Council-University of Glasgow Centre for Virus Research
  • 直, 亨則
    Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University; One Health Research Center, Hokkaido University
  • 板倉, 友香里
    Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University
  • 出口, 清香
    Center for iPS Cell Research and Application (CiRA), Kyoto University
  • 鈴木, 理滋
    Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University
  • 王, 磊
    Department of Cancer Pathology, Faculty of Medicine, Hokkaido University; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University
  • Begum, MST Monira
    Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University
  • 喜多, 俊介
    Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University
  • 矢島, 久乃
    Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University
  • 佐々木, 慈英
    Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University
  • 田畑, 香織
    Department of Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University
  • 清水, 凌
    Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University
  • 津田, 真寿美
    Department of Cancer Pathology, Faculty of Medicine, Hokkaido University; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University
  • 小杉, 優介
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo; Graduate School of Medicine, The University of Tokyo
  • 藤田, 滋
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo; Graduate School of Medicine, The University of Tokyo
  • 潘, 琳
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo; Graduate School of Frontier Sciences, The University of Tokyo
  • Sauter, Daniel
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo; Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen
  • 吉松, 組子
    Institute for Genetic Medicine, Hokkaido University
  • 鈴木, 紗織
    Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University
  • 浅倉, 弘幸
    Tokyo Metropolitan Institute of Public Health
  • 長島, 真美
    Tokyo Metropolitan Institute of Public Health
  • 貞升, 健志
    Tokyo Metropolitan Institute of Public Health
  • 吉村, 和久
    Tokyo Metropolitan Institute of Public Health
  • 山本, 佑樹
    HiLung, Inc.
  • 永元, 哲治
    HiLung, Inc.
  • Schreiber, Gideon
    Department of Biomolecular Sciences, Weizmann Institute of Science
  • 前仲, 勝実
    Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University; Global Station for Biosurfaces and Drug Discovery, Hokkaido University; Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University
  • The Genotype to Phenotype Japan (G2P-Japan)
  • 橋口, 隆生
    Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University; CREST, Japan Science and Technology Agency
  • 池田, 輝政
    Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University
  • 福原, 崇介
    Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University; AMED-CREST, Japan Agency for Medical Research and Development (AMED); Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University
  • 齊藤, 暁
    Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki; Center for Animal Disease Control, University of Miyazaki
  • 田中, 伸哉
    Department of Cancer Pathology, Faculty of Medicine, Hokkaido University; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University
  • 松野, 啓太
    Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University; One Health Research Center, Hokkaido University; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University
  • 高山, 和雄
    Center for iPS Cell Research and Application (CiRA), Kyoto University; CREST, Japan Science and Technology Agency
  • 佐藤, 佳
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo; Graduate School of Medicine, The University of Tokyo; Graduate School of Frontier Sciences, The University of Tokyo; CREST, Japan Science and Technology Agency; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus infection, Kumamoto University

説明

In late 2022, SARS-CoV-2 Omicron subvariants have become highly diversified, and XBB is spreading rapidly around the world. Our phylogenetic analyses suggested that XBB emerged through the recombination of two cocirculating BA.2 lineages, BJ.1 and BM.1.1.1 (a progeny of BA.2.75), during the summer of 2022. XBB.1 is the variant most profoundly resistant to BA.2/5 breakthrough infection sera to date and is more fusogenic than BA.2.75. The recombination breakpoint is located in the receptor-binding domain of spike, and each region of the recombinant spike confers immune evasion and increases fusogenicity. We further provide the structural basis for the interaction between XBB.1 spike and human ACE2. Finally, the intrinsic pathogenicity of XBB.1 in male hamsters is comparable to or even lower than that of BA.2.75. Our multiscale investigation provides evidence suggesting that XBB is the first observed SARS-CoV-2 variant to increase its fitness through recombination rather than substitutions.

収録刊行物

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ